This study is looking into whether guselkumab, a medication for psoriasis, can help prevent or reduce joint problems in people with high-risk psoriasis. Researchers believe that ongoing skin inflammation and certain changes seen on ultrasound (musculoskeletal power Doppler ultrasound or MSK-PDUS) might increase the risk of developing psoriatic arthritis (PsA). Guselkumab targets a specific molecule (IL-23) involved in this process. The study aims to see if guselkumab can improve MSK-PDUS findings within 24 weeks and reduce the development of joint issues over two years. You might be able to join if you are 18 or older, have had psoriasis for at least two years, and meet other specific criteria. The study is currently recruiting 176 participants.

Study design

This is a multi-center, randomized, double-blind, placebo-controlled study involving 176 participants. Participants will receive either guselkumab or a placebo.

What's involved

Participants will receive subcutaneous injections of guselkumab or placebo at Week 0, Week 4, and every 8 weeks thereafter. MSK-PDUS will be measured at Baseline and Week 24.

Compensation

Not stated in the trial record.

Follow-up

The study will track changes in MSK-PDUS at 24 weeks and the emergence of joint problems for up to two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.